Deerfield Management Company, L.P. (Series C) Fate Therapeutics Inc Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,555,871 shares of FATE stock, worth $5.9 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

3,555,871

Previous 3,555,871 -0.0%

Holding current value

$5.9 Million

Previous $11.7 Million 6.7%

% of portfolio

0.23%

Previous 0.24%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $4.45 Million - $9.67 Million	1,365,463 Added 62.34%	3,555,871 $11.7 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $7.75 Million - $18.3 Million	2,190,408 New	2,190,408 $16.1 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $17.3 Million - $23.3 Million	-362,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $3.44 Million - $5.55 Million	58,000 Added 19.08%	362,000 $21.5 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $18.8 Million - $30.5 Million	-260,067 Reduced 46.11%	304,000 $25.1 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $3.96 Million - $10.5 Million	-104,000 Reduced 15.57%	564,067 $51.3 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $7.47 Million - $9.95 Million	-245,708 Reduced 26.89%	668,067 $26.7 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $14.2 Million - $24.8 Million	-703,218 Reduced 43.49%	913,775 $31.4 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $6.66 Million - $12.3 Million	-385,612 Reduced 19.26%	1,616,993 $35.9 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $665,590 - $1.03 Million	49,708 Added 2.55%	2,002,605 $39.2 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $3.87 Million - $5.63 Million	250,000 Added 14.68%	1,952,897 $30.3 Million
Q1 2019 May 15, 2019	BUY	$13.15 - $18.71 $631,620 - $898,678	48,032 Added 2.9%	1,702,897 $29.9 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $5.52 Million - $8.17 Million	481,248 Added 41.01%	1,654,865 $21.2 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $10.3 Million - $19.1 Million	1,173,617 New	1,173,617 $19.1 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account

Deerfield Management Company, L.P. (Series C) Fate Therapeutics Inc Transaction History